ANXA3 and stroke disorder: In vivo administration of hADMSCs loaded with the therapeutic peptide p5 to post-stroke rats led to improvement in functional recovery and increased number of surviving transplanted cells, most likely by reducing the number of inflammatory ANXA3/IbaI-positive cells in the peri-infarcted region.